Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease of the motor system, characterized by selective andAmyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease of the motor system, characterized by selective andprogressive loss of motor neurons, eventually leading to paralysis and death within 2–5 years .iPSC-derived motor neurons areiPSC-derived motor neurons arevaluable tools for biochemical analysis, disease modelling and clinical application of this disease. Cytoplasmic accumulation andnuclear loss of the RNA binding protein transactive response DNA-binding protein 43 (TDP-43) from affected neurons in most instances of ALS [2-3]. Over 40 dominantly inherited mutations in the gene encoding TDP-43 have subsequently been identified in familial ALS patients , implicating TDP-43 dysfunction in the vast majority of ALS cases.
Human Motor Neurons (iPSC-derived, TDP-43 mutation, M337V, HOM) is derived from a genetically modified normal iPSC lineis derived from a genetically modified normal iPSC linecarrying the homozygous M337V mutation in the TDP43 gene (Figure 1). iXCells™ hiPSC-derived motor neurons express typicalmarkers of motor neurons, e.g. HB9 (MNX1), ISL1, CHAT, with the purity higher than 85%. iXCells™ motor neurons are available inboth cryopreserved vials (2 million cells/vial) and fresh plate formats (12-well plate or 96-well plate). Most of the cells will express high level of of HB9 and ISL-1 after thawing in the Motor Neuron Culture Medium Kit (Cat# MD-0022-100ML). And after cultured in the mediumfor 5-7 days, these cells will express high levels of CHAT and MAP2.
Figure 1.Homozygous M337V mutation (highlighted) has been introduced to TDP-43 gene using CRISPR/Cas9 based genome editing technology. The targeted site is verified by genomic PCR/Sanger sequencing.
|Tissue Origin||Human iPSC-derived motor neurons (TDP-43 mutation, M337V, homozygous)|
|Package Size||1.0 million cells/vial; 2.0 million cells/vial|
|Media||iXCells™ Motor Neuron Culture Medium Kit (Cat# MD-0022-100ML)|
 Taylor, J. P., Brown, R. H. Jr & Cleveland, D. W. Decoding ALS: from genes to mechanism. Nature 539, 197–206 (2016).
 Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).
 Ling, S. C., Polymenidou, M. & Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79, 416–438 (2013).
 Lagier-Tourenne, C., Polymenidou, M. & Cleveland, D. W. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 19, R46–R64 (2010).